CytomX Therapeutics Inc (CTMX)
0.89
+0.02
(+2.71%)
USD |
NASDAQ |
Nov 22, 16:00
0.8913
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Profit Margin (Quarterly): 17.16% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 17.16% |
| June 30, 2024 | -26.02% |
| March 31, 2024 | 33.26% |
| December 31, 2023 | 3.15% |
| September 30, 2023 | 11.34% |
| June 30, 2023 | -4.40% |
| March 31, 2023 | -14.09% |
| December 31, 2022 | -43.61% |
| September 30, 2022 | -260.7% |
| June 30, 2022 | -229.5% |
| March 31, 2022 | -353.8% |
| December 31, 2021 | |
| September 30, 2021 | -128.4% |
| June 30, 2021 | -118.1% |
| March 31, 2021 | -97.39% |
| December 31, 2020 | |
| September 30, 2020 | -82.70% |
| June 30, 2020 | -94.41% |
| March 31, 2020 | 24.61% |
| December 31, 2019 | |
| September 30, 2019 | -221.2% |
| Date | Value |
|---|---|
| June 30, 2019 | -321.3% |
| March 31, 2019 | -47.90% |
| December 31, 2018 | -281.0% |
| September 30, 2018 | -187.3% |
| June 30, 2018 | -63.02% |
| March 31, 2018 | -109.2% |
| December 31, 2017 | 2.29% |
| September 30, 2017 | -42.44% |
| June 30, 2017 | -288.1% |
| March 31, 2017 | -70.86% |
| December 31, 2016 | -223.7% |
| September 30, 2016 | -424.5% |
| June 30, 2016 | -458.2% |
| March 31, 2016 | -721.1% |
| December 31, 2015 | -577.8% |
| September 30, 2015 | -612.2% |
| June 30, 2015 | -284.2% |
| March 31, 2015 | -356.5% |
| December 31, 2014 | -257.2% |
| September 30, 2014 | -187.4% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-353.8%
Minimum
Mar 2022
33.26%
Maximum
Mar 2024
-80.21%
Average
-43.61%
Median
Dec 2022
Profit Margin (Quarterly) Benchmarks
| Spero Therapeutics Inc | -219.3% |
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | 7.63% |
| Operating Margin (Quarterly) | 12.30% |
| Return on Net Operating Assets | 64.47% |